68 results about "Podocyte" patented technology

This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

The present invention relates to methods for treating or preventing podocyte-related diseases and disorders using compounds that modulate the calcium sensing receptor or pharmaceutical compositions comprising thereof.

The invention provides compositions, methods and systems for the ex vivo co-culture of renal cells, more specifically, for the co-culture of glomerulus-derived vascular endothelial cells and podocyte cells using apparatus that mimics the in vivo cellular architecture of the renal corpuscle. The invention described herein finds a variety of uses, for example, as a model system for the study of renal corpuscle function, including the filtration of the blood supply that occurs at the interface of the glomerulus and Bowman's capsule, normal physiology of those cell types, and as a model system for the study of renal disease, including the study of drug effects on the functioning of these cell types.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The present invention relates to methods for treating and / or preventing podocytes related disorders and / or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and / or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and / or nephrotic syndrome.

The invention belongs to the field of biological recognition, and discloses a cell detection method, device and apparatus for a glomerular pathological section image, and the method comprises the steps: obtaining a to-be-detected glomerular pathological section image; inputting the to-be-detected glomerular pathological section image into a preset neural network model for identification and detection, with the preset neural network model being obtained by training a neural network through a predetermined number of glomerular pathological section images for identifying and labeling mesangial cells, endothelial cells and podocytes; respectively outputting probability graphs of mesangial cells, endothelial cells and podocytes in the glomerular pathological section image to be detected from three output channels of a preset neural network model; and calculating the number of the mesangial cells, the endothelial cells and the podocytes in the glomerular pathological section image to be detected according to the probability graphs of the mesangial cells, the endothelial cells and the podocytes. The causes and conditions of the patient are determined according to the number of mesangial cells, endothelial cells and podocyte, and a treatment scheme is made accurately.

Compositions which specifically block cathepsin L function in podocytes, compositions which protect cytoskeletal adaptor protein (CD2AP) for degradation, compositions which modulate expression or function of cytoskeletal adaptor protein (CD2AP), protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions.

The invention discloses an extracting and in-vitro multiplication culture technical method of urine-derived mesenchymal stem cells (USCs). In-vitro multiplication is mainly conducted in the mode thatthe mesenchymal stem cells (MSCs) are separated from sterile urine, and a culture medium easy to prepare is adopted; the extracted USCs subjected to multiplication culture can be used for therapy of clinical immunology related diseases and damage repair of various tissue and organs; the extracting and in-vitro multiplication culture technical method has the advantages that the separating and extracting processes of the USCs are completely free of wounds, special instruments are not needed, the cost is low, and the extracting process is easy to accept by patients; the USCs have other advantagesof being capable of achieving autotransplantation, free of immune rejection response and ethical arguments, and capable of avoiding the pathophoresis risk; and the USCs show the good multiplication ability, and the number of the cells needed during cell therapy can be met.

Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are identified.

This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

The present invention identifies that glomeruli express many neuron-specific and especially synapse-specific protein similarities. In particular, the present invention identifies Rab3A expression, including the expression of altered forms, as well as expression of other synapse-specific proteins including neurotransmitter receptors. The invention further identifies that modulation of the activity of these synapse-specific proteins results in modulation of podocytes.

The invention provides a novel purpose of a microRNA-30 family, and concretely to an application of the family used as a podocyte injury marker for patients with focal segmental glomerulosclerosis (FSGS). In addition, the invention further provides an application of the microRNA-30 family in preparation of medicaments for treating the podocyte injury. According to the invention, the microRNA-30 family facilitates diagnosis for the patients with the focal segmental glomerulosclerosis (FSGS) and the preparation of the medicaments for treating the podocyte injury, and thus has an extremely important significance for diagnosis and treatment of chronic kidney diseases.

The present invention describes a non-invasive method to isolate with high efficiency, purity and reproducibility the population of renal progenitors CD133+CD24+, from urine samples of patients suffering from various glomerular diseases. Said renal progenitors can then easily be induced to differentiate into podocytes. The isolation of renal progenitors with the method of the invention allows the use of said cells as a cellular model of a disease for the in vitro study of genetic excluding exfoliated epithelial cells and blood cells mutations due to the podocyte or for the study of renal toxicity induced by potentially nephrotoxic drugs on the tubules.

The invention discloses a traditional Chinese medicine composition for treating diabetic nephropathy. The traditional Chinese medicine composition is prepared from, by weight, 15-60 parts of cherokeerose fruits, 15-60 parts of gorgon fruits, 15-60 parts of fructus rubi, 15-60 parts of the seeds of Chinese dodder, 5-15 parts of tripterygium glycosides and 15-60 parts of herba leonuri. The invention further provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in treating proteinuria of patients who suffer from the diabetic nephropathy. The traditional Chinese medicine composition is based on experience of famous veteran doctors of traditional Chinese medicine in Jiangsu province, the traditional Chinesemedicine composition has the functions of tonifying the kidney to arrest spontaneous emission and clearing and dispersing blood stasis, and is used for treating the proteinuria of the patients who suffer from early and mid-term diabetic nephropathy. Through clinical pharmacodynamic experiments, it is shown that the traditional Chinese medicine composition can reduce the proteinuria of the patients who suffer from diabetic nephropathy III, and there are no adverse reactions in the experiment process; through in-vivo pharmacological experiments, it is shown that the traditional Chinese medicinecomposition can reduce podocyte injury associated with diabetic nephropathy inflammation, the structures and the functions of podocytes are improved, and the proteinuria is reduced.

The invention discloses a method used for determining change of podocyte skelemin and marker protein of podocyte skelemin in acute hypertensive renal injury. The method is characterized in comprising steps: mouse acute hypertension models are established; podocyte damage caused by participation of GSK3beta / beta-catenin signal path in acute hypertension is determined, wherein Western blot, and RQ-PCR are used for determining expression of the protein above and mRNA; in vitro culturing of podocyte is carried out so as to study regulation mechanisms of GSK3beta / beta-catenin signal path on podocyte-associated proteins and cytoskeletal proteins, and illustrate start-up functions and core effects of GSK3beta / beta-catenin signal path in acute hypertension podocyte damage further. According to the method, living body freezing technology is combined with freezing substitution for research on podocyte damage when hemodynamics changes, and contribution is provided for development of a method used for preventing and reducing podocyte damage, reducing proteinuria, and providing new therapeutic targets.

The invention provides a method of assigning to a patient a likelihood of having a kidney disease, or a likelihood of undergoing kidney transplant rejection, comprising the steps of providing a urinesample from the patient and determining the concentration of T cells, podocytes and proximal tubular epithelial cells. The ratios of these cell types are used for determining the risk of a kidney disease or transplant rejection.

This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.

The Inventors established an efficient, chemically defined protocol for differentiating hPSCs into multi-potent nephron progenitor cells (NPCs) that can form nephron-like structures. By recapitulating metanephric kidney development in vitro, the Inventors generate SIX2+SALL1+WT1+PAX2+ NPCs with 90% efficiency within 9 days of differentiation. The NPCs possess the developmental potential of their in vivo counterparts and form PAX8+LHX1+ renal vesicles that self-pattern into nephron structures. In both 2D and 3D culture, NPCs form kidney organoids containing epithelial nephron-like structures expressing markers of podocytes, proximal tubules, loops of Henle, and distal tubules in an organized, continuous arrangement that resembles the nephron in vivo. The Inventors also show that this organoid culture system can be used to study mechanisms of human kidney development and toxicity.

The following disclosure generally relates to methods of culturing podocytes in vitro. The cultures can be used for drug screening (such as medium or high throughput drug screening), and for studying molecular pathways involved in glomerular diseases. The disclosure also provides methods for analyzing the healthiness of podocytes in a cell culture. The disclosure also relates to diagnosis of kidney diseases.

The invention relates to a cultivation method for a mouse with a kidney podocyte specific knockout lncRNA DLX6-os1 transgene. The method can effectively achieve the effect of studying the action mechanism of podocyte injuries in different kidney diseases; according to the technical scheme, multi-generation crossbreeding is performed on an FLOX-DLX6-os1 transgenic mouse constructed in the earlier stage and another transgenic mouse carrying a podocyte specific NPHS2-Cre gene through a genetic engineering technology, and the cultivation of the mouse with the kidney podocyte specific knockout lncRNA DLX6-os1 transgene is achieved. The cultivation method for the mouse with the kidney podocyte specific knockout lncRNA DLX6-os1 transgene provides a very good animal model for defining the role ofthe lncRNA DLX6-os1 in the podocyte injuries, effectively achieves the effect of studying the action mechanism of the podocyte injuries in the different kidney diseases, and is an innovation of the cultivation method of transgenic mice.

Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are indentified.

Methods of treating kidney disease and protecting podocytes from injury are provided. Methods of screening agents for the treatment of kidney disease are also provided. In addition, methods of identifying structural or functional defects in a patient's podocytes and methods of identifying kidney disease causing agents in a patient's biological sample are also provided.

The following disclosure generally relates to methods of culturing podocytes in vitro. The cultures can be used for drug screening (such as medium or high throughput drug screening), and for studying molecular pathways involved in glomerular diseases. The disclosure also provides methods for analyzing the healthiness of podocytes in a cell culture. The disclosure also relates to diagnosis of kidney diseases.

This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

The invention belongs to the technical field of biochemistry, and provides a preparation method of human renal podocytes. The human renal podocytes conforms to an expression result of a human renal podocyte marker; and meanwhile, the preparation method is good in repeatability and simple to operate, and the human renal podocytes with high yield, higher value-added rate and high purity can be obtained.

The present invention identifies that glomeruli express many neuron-specific and especially synapse-specific protein similarities. In particular, the present invention identifies Rab3A expression, including the expression of altered forms, as well as expression of other synapse-specific proteins including neurotransmitter receptors. The invention further identifies that modulation of the activity of these synapse-specific proteins results in modulation of podocytes.

There is provided a method for promoting dynamin ring formation and / or maintenance of dynamin rings in a cell, comprising treating the cell with an effective amount of a dynamin ring stabilizer, or a prodrug or pharmaceutically acceptable salt of the dynamin ring stabilizer. The maintenance or accumulation of dynamin ring formation has particular application in the prophylaxis or treatment of a kidney disease or condition characterized by proteinuria. A dynamin ring stabilizer can be any agent that interacts with dynamin to promote dynamin ring assembly and / or inhibit dynamin ring disassembly. There are also provided methods for prophylaxis or treatment of podocyte dysfunction and / or maintaining or inducing actin cytoskeleton formation in a cell utilizing dynamin ring stabilizers, and for screening a test agent for use as a dynamin ring stabilizer.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.